STOCK TITAN

Biogen (BIIB) awards 8,450 restricted stock units to its CFO

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Biogen Inc. reported that Chief Financial Officer Robin Kramer acquired 8,450 restricted stock units as a grant on February 13, 2026. The RSUs were awarded at a price of $0.00 per unit, reflecting equity-based compensation rather than an open-market purchase.

According to the footnote, these restricted stock units vest in three equal yearly installments, beginning on the first anniversary of the grant date of February 13, 2026. After this grant, Kramer directly holds 8,450 RSUs, which may convert into Biogen shares as they vest.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kramer Robin

(Last) (First) (Middle)
225 BINNEY STREET

(Street)
CAMBRIDGE MA 02142

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC. [ BIIB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit $0 02/13/2026 A 8,450 (1) 02/13/2029 Common Stock 8,450 $0 8,450 D
Explanation of Responses:
1. The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026.
/s/ Wendell Taylor, attorney-in-fact for Robin Kramer 02/17/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Biogen (BIIB) report for CFO Robin Kramer?

Biogen reported that CFO Robin Kramer received a grant of 8,450 restricted stock units on February 13, 2026. These units are equity-based compensation, not an open-market share purchase, and will vest over time according to the award’s schedule.

How many restricted stock units were granted to Biogen CFO Robin Kramer?

Robin Kramer was granted 8,450 restricted stock units. This entire amount was reported as acquired in a single award dated February 13, 2026, and represents stock-based compensation that can settle in Biogen shares as the units vest over the coming years.

What is the vesting schedule for Robin Kramer’s Biogen restricted stock units?

The 8,450 restricted stock units vest in three equal yearly installments. Vesting begins on the first anniversary of the February 13, 2026 grant date, meaning one-third vests each year over three years, subject to the award’s terms remaining in effect.

Did Biogen CFO Robin Kramer buy or sell shares on the open market?

The filing shows an acquisition through a grant of restricted stock units, not an open-market trade. Transaction code “A” denotes a grant or award, with 8,450 RSUs received at a price of $0.00 per unit as part of compensation.

How many Biogen restricted stock units does Robin Kramer hold after this grant?

After the reported transaction, Robin Kramer holds a total of 8,450 restricted stock units directly. This figure reflects the newly granted award, which will vest in three equal annual installments beginning on the first anniversary of the grant date.
Biogen Inc

NASDAQ:BIIB

BIIB Rankings

BIIB Latest News

BIIB Latest SEC Filings

BIIB Stock Data

28.84B
146.46M
Drug Manufacturers - General
Biological Products, (no Diagnostic Substances)
Link
United States
CAMBRIDGE